Evidence map›Paper›PMID 36307514›Full record

Trial reportScientific reports2022

Assessment of the exposure to selected smoke constituents in adult smokers using in-market heated tobacco products: a randomized, controlled study.

Dai Yuki, Akira Kikuchi, Takuya Suzuki, Chikako Sakaguchi, Danting Huangfu, Yasufumi Nagata, Aoi Kakehi

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dai YukiScientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927, Japan. dai.yuki@jt.com.
Akira KikuchiScientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927, Japan.
Takuya SuzukiScientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927, Japan.
Chikako SakaguchiScientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927, Japan.
Danting HuangfuScientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927, Japan.
Yasufumi NagataScientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927, Japan.
Aoi KakehiScientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927, Japan.
Japan Tobacco (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objectives of this clinical study were to demonstrate a reduction in exposure to selected harmful and potentially harmful constituents (HPHCs) in Japanese healthy adult smokers who switched to four in-market heated tobacco products. Eighty-nine smokers were randomly assigned for five days to one of six study groups: four groups who switched to one of the commercially available heated tobacco products; a group who continued to smoke their own brand of combustible cigarettes (CC); or a group who stopped smoking (SS). Fifteen biomarkers of exposure (BoE) to 14 HPHCs and pyrene were measured at baseline, Day 3 and Day 5 in 24 h urine and breath, under clinical confinement. Product consumption, nicotine uptake and subjective effects were also measured before and after product switching. On Day 5, significant reductions in most BoE relative to the CC group were observed after switching to heated tobacco products. No changes in BoE were observed between baseline and Day 5 in the CC group. Significantly, the magnitude of the reduction in exposure to most of the selected HPHCs observed in the heated tobacco product groups was close to that observed in the SS group.

Indexed as

Electronic Nicotine Delivery SystemsTobacco ProductsAdultBiomarkersHumansNicotineSmokersBiomarkersNicotine

Identifiers

PMID36307514
PMCPMC9616951
OpenAlexW4307721920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.